Ranbaxy Laboratories, India’s largest pharmaceutical company, has been issued import alert by US Food & Drug Administration (USFDA) on September 13 for its Mohali unit. The import alert was issued due to non-compliance with drug good manufacturing practices (GMPs).
The Mohali unit was already issued Form 483 in May 2012 signifying that there were certain manufacturing practices, which the USFDA had already pointed out and the company had time to comply the problems, which USFDA had brought up. However, since Ranbaxy could not comply to those issues the 483 has now converted to an import alert.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: